The lectin‐like domain of thrombomodulin is a drug candidate for both prophylaxis and treatment of liver ischemia and reperfusion injury in mice

Ischemia and reperfusion injury (IRI) can occur in any tissue or organ. With respect to liver transplantation, the liver grafts from donors by definition experience transient ischemia and subsequent blood reflow. IRI is a problem not only in organ transplantation but also in cases of thrombosis or circulatory disorders such as mesenteric ischemia, myocardial, or cerebral infarction. We have reported that recombinant human soluble thrombomodulin (rTM), which is currently used in Japan to treat disseminated intravascular coagulation (DIC), has a protective effect and suppresses liver IRI in mice. However, rTM may not be fully safe to use in humans because of its inherent anticoagulant activity. In the present study, we used a mouse liver IRI model to explore the possibility that the isolated lectin-like domain of rTM (rTMD1), which has no anticoagulant activity, could be effective as a therapeutic modality for IRI. Our results indicated that rTMD1 could suppress ischemia and reperfusion-induced liver damage in a dose-dependent manner without concern of associated hemorrhage. Surprisingly, rTMD1 suppressed the liver damage even after IR insult had occurred. Taken together, we conclude that rTMD1 may be a candidate drug for prevention of and therapy for human liver IRI without the possible risk of hemorrhage

Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K‐RAS status for unresectable colorectal liver metastasis (BECK study): Long‐term results of survival

[Background/Purpose]To investigate the long‐term outcome and entire treatment course of patients with technically unresectable CRLM who underwent conversion hepatectomy and to examine factors associated with conversion to hepatectomy. [Methods]Recurrence and survival data with long‐term follow‐up were analyzed in the cohort of a multi‐institutional phase II trial for technically unresectable colorectal liver metastases (the BECK study). [Results]A total of 22/12 patients with K‐RAS wild‐type/mutant tumors were treated with mFOLFOX6 + cetuximab/bevacizumab. The conversion R0/1 hepatectomy rate was significantly higher in left‐sided primary tumors than in right‐sided tumors (75.0% vs 30.0%, P = .022). The median follow‐up was 72.6 months. The 5‐year overall survival (OS) rate in the entire cohort was 48.1%. In patients who underwent R0/1 hepatectomy (n = 21), the 5‐year RFS rate and OS rate were 19.1% and 66.3%, respectively. At the final follow‐up, seven patients had no evidence of disease, five were alive with disease, and 20 had died from their original cancer. All 16 patients who achieved 5‐year survival underwent conversion hepatectomy, and 11 of them underwent further resection for other recurrences (median: 2, range: 1‐4). [Conclusions]Conversion hepatectomy achieved a similar long‐term survival to the results of previous studies in initially resectable patients, although many of them experienced several post‐hepatectomy recurrences. Left‐sided primary was found to be the predictor for conversion hepatectomy

Ruthenium-Catalyzed Addition of Aromatic Amides to Internal Alkynes and Subsequent Intramolecular Cyclization for the Atom-Economical Synthesis of Isoindolinones

A selective and atom-economical synthesis of isoindolinones is described. This novel synthetic strategy involves two catalytic reactions: the ruthenium-catalyzed regioselective alkenylation of aromatic C–H bond of aromatic amides with internal alkynes, and subsequent intramolecular cyclization of the resulting alkene with amide functionalities. The addition of only a catalytic amount of bases is required for efficient construction of the desired isoindolinones, and no byproducts are formed in the tandem catalytic reactions. Various kinds of aromatic amides and internal alkynes can be used in the present reactions, and the corresponding isoindolinones bearing a quaternary carbon at the C3 position are obtained in good to high yields

Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K‐RAS status for unresectable colorectal liver metastasis (BECK study): Long‐term results of survival

[Background/Purpose]To investigate the long‐term outcome and entire treatment course of patients with technically unresectable CRLM who underwent conversion hepatectomy and to examine factors associated with conversion to hepatectomy. [Methods]Recurrence and survival data with long‐term follow‐up were analyzed in the cohort of a multi‐institutional phase II trial for technically unresectable colorectal liver metastases (the BECK study). [Results]A total of 22/12 patients with K‐RAS wild‐type/mutant tumors were treated with mFOLFOX6 + cetuximab/bevacizumab. The conversion R0/1 hepatectomy rate was significantly higher in left‐sided primary tumors than in right‐sided tumors (75.0% vs 30.0%, P = .022). The median follow‐up was 72.6 months. The 5‐year overall survival (OS) rate in the entire cohort was 48.1%. In patients who underwent R0/1 hepatectomy (n = 21), the 5‐year RFS rate and OS rate were 19.1% and 66.3%, respectively. At the final follow‐up, seven patients had no evidence of disease, five were alive with disease, and 20 had died from their original cancer. All 16 patients who achieved 5‐year survival underwent conversion hepatectomy, and 11 of them underwent further resection for other recurrences (median: 2, range: 1‐4). [Conclusions]Conversion hepatectomy achieved a similar long‐term survival to the results of previous studies in initially resectable patients, although many of them experienced several post‐hepatectomy recurrences. Left‐sided primary was found to be the predictor for conversion hepatectomy

Typo EINA 15 years

Aquest llibre commemora els 15 anys dels cursos de tipografia a Eina. Han estat 15 edicions de durades i continguts diferents però que sempre han considerat la lletra com la manera per entendre i construir la pàgina. Les primeres tres edicions no van tenir cap mena de tiulació per després passar a un postgrau i finalment a un màster de títol propi de la Universitat Autònoma de Barcelona. A les pàgines següents, trobareu les dates, la llista de professors i la llista d’alumnes de cada curs i, a continuació, una tria de treballs destacats d’alguns alumnes que han cursat els estudis. En fer aquesta publicació, un cop acabada la tria, és quan ens hem adonat de la importància d’allò que ha deixat el curs i de com de diferents són els ambits relacionats amb la lletra.Este libro conmemora los 15 años de los cursos de tipografía en Eina. Han sido 15 ediciones de duraciones y contenidos diferentes pero que siempre han considerado la letra como la forma de entender y construir la página. Las primeras tres ediciones no tuvieron forma de titulación alguna, para después pasar a un posgrado y finalmente a un máster de título propio en la Universitat Autònoma de Barcelona. Encontraréis en la siguientes páginas las fechas, la lista de profesores y la lista de alumnos de cada curso, y a continuación una selección de trabajos destacados de quienes pasaron por los cursos. Al hacer esta publicación, una vez terminada la selección, es cuando nos hemos dado cuenta de cómo de importante es lo que ha dejado el curso y de cómo de diferentes son los ámbitos relacionados con la letra.This book commemorates 15 years of typography courses at Eina. These courses have had different lengths and contents, but all have considered the letter as the key to understanding and building the page. For the first three years, there was no formal degree attached to the program, but Typography later became a postgraduate degree and finally an accredited Master´s degree from Autonomous University of Barcelona. In the following pages you’ll find the dates, professors and students of each year of the program, followed by a selection of outstanding projects. Putting this publication together was a reminder of just how important this course is, and of the many different ways there are of thinking about letters